谷歌浏览器插件
订阅小程序
在清言上使用

Human -Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES(2021)

引用 0|浏览6
暂无评分
摘要
Fabry disease (FD) is a lysosomal storage disease caused by mutations in the gene for the alpha-galactosidase A (GLA) enzyme. The absence of the enzyme or its activity results in the accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in different tissues, leading to a wide range of clinical manifestations. More than 1000 natural variants have been described in the GLA gene, most of them affecting proper protein folding and enzymatic activity. Currently, FD is treated by enzyme replacement therapy (ERT) or pharmacological chaperone therapy (PCT). However, as both approaches show specific drawbacks, new strategies (such as new forms of ERT, organ/cell transplant, substrate reduction therapy, or gene therapy) are under extensive study. In this review, we summarize GLA mutants described so far and discuss their putative application for the development of novel drugs for the treatment of FD. Unfavorable mutants with lower activities and stabilities than wild-type enzymes could serve as tools for the development of new pharmacological chaperones. On the other hand, GLA mutants showing improved enzymatic activity have been identified and produced in vitro. Such mutants could overcome several complications associated with current ERT, as lower-dose infusions of these mutants could achieve a therapeutic effect equivalent to that of the wild-type enzyme.
更多
查看译文
关键词
alpha-galactosidase A,Fabry disease,pharmacological chaperones,rare diseases,enzyme replacement therapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要